Nucleoside analogues as highly potent and selective inhibitors of herpes simplex virus thymidine kinase.

[1]  P. Jones.  Strategies for Antiviral Drug Discovery , 1998, Antiviral chemistry & chemotherapy.

[2]  H. Simmonite,et al.  The design, synthesis and properties of highly potent and selective inhibitors of herpes simplex virus types 1 and 2 thymidine kinase. , 1998, Antiviral chemistry & chemotherapy.

[3]  A. Moffatt,et al.  Inhibition of virus-encoded thymidine kinase suppresses herpes simplex virus replication in vitro and in vivo. , 1998, Antiviral chemistry & chemotherapy.

[4]  G. Maga,et al.  Synthesis, properties, and pharmacokinetic studies of N2-phenylguanine derivatives as inhibitors of herpes simplex virus thymidine kinases. , 1995, Journal of medicinal chemistry.

[5]  P. Griffiths,et al.  Clinical Management of Herpes Viruses , 1995 .

[6]  G. Bisacchi,et al.  (2R, 4S, 5S)-1-(tetrahydro-4-hydroxy-5-methoxy-2-furanyl)thymine: a potent selective inhibitor of herpes simplex thymidine kinase , 1993 .

[7]  J. Brunvoll,et al.  Fluoroalkyl Thieno- and Benzo-Fused gamma-Lactones. , 1993 .

[8]  J. D. Karkas,et al.  Assessment of a selective inhibitor of herpes simplex virus thymidine kinase (L-653,180) as therapy for experimental recurrent genital herpes , 1992, Antimicrobial Agents and Chemotherapy.

[9]  G. Maga,et al.  Quantitative structure-activity relationships of N2-phenylguanines as inhibitors of herpes simplex virus thymidine kinases. , 1992, Journal of medicinal chemistry.

[10]  Y. Cheng,et al.  Suppression of ocular herpes recurrences by a thymidine kinase inhibitor in squirrel monkeys. , 1991, Antiviral research.

[11]  R. Tenser.  Role of herpes simplex virus thymidine kinase expression in viral pathogenesis and latency. , 1991, Intervirology.

[12]  J. T. ter Maaten,et al.  Pharmacokinetics of cefepime in patients with respiratory tract infections , 1990, Antimicrobial Agents and Chemotherapy.

[13]  Jin‐Pei Cheng,et al.  Determination and interrelation of bond heterolysis and homolysis energies in solution , 1990 .

[14]  G. Zanardi,et al.  On the neophyl-like rearrangement of 2-(9-anthryl)ethyl radicals , 1989 .

[15]  K. Tyler,et al.  Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[16]  I. Duncan,et al.  New Potent and Selective Inhibitors of Herpes Simplex Virus Tbyhidine Kinase , 1989 .

[17]  J. D. Karkas,et al.  A Potent, Selective, Non-Substrate Inhibitor of HSV-I Thymidine Kinase: (±)-9-[[(Z)-2-(Hydroxymethyl)Cyclohexyl]Methyl]Guanine and Related Compounds , 1989 .

[18]  S Spadari,et al.  N2-phenyldeoxyguanosine: a novel selective inhibitor of herpes simplex thymidine kinase. , 1988, Journal of medicinal chemistry.

[19]  R. T. Walker,et al.  Inhibition of the Herpes Simplex Virus Thymidine Kinase by 5 Substituted Thymidine Analogues. Comparison of the Types 1 and 2 Enzymes , 1988 .

[20]  Y. Cheng,et al.  Demonstration of viral thymidine kinase inhibitor and its effect on deoxynucleotide metabolism in cells infected with herpes simplex virus , 1987, Antimicrobial Agents and Chemotherapy.

[21]  J. Koketsu,et al.  Reduction of Aromatic Ketones or Thioketones with Phenylphosphine , 1985 .

[22]  A. Markham,et al.  Synthesis of some 5'-amino-2',5'-dideoxy-5-iodouridine derivatives and their antiviral properties against herpes simplex virus. , 1982, Antiviral research.

[23]  Yung‐chi Cheng.  A RATIONAL APPROACH TO THE DEVELOPMENT OF ANTIVIRAL CHEMOTHERAPY: ALTERNATIVE SUBSTRATES OF HERPES SIMPLEX VIRUS TYPE 1 (HSV‐1) AND TYPE 2 (HSV‐2) THYMIDINE KINASE (TK) * , 1977, Annals of the New York Academy of Sciences.

[24]  J. Subak-Sharpe,et al.  Induction of both thymidine and deoxycytidine kinase activity by herpes viruses. , 1974, The Journal of general virology.

[25]  T. Jojima,et al.  Pyridazines. I. Novel Intramolecular Cycloaddition of 3-Chloro-6-(2-allylphenoxy) pyridazines , 1972 .